Folate metabolism gene 5,10-methylenetetrahydrofolate reductase (MTHFR) is associated with ADHD in myelomeningocele patients
- PMID: 23227261
- PMCID: PMC3515551
- DOI: 10.1371/journal.pone.0051330
Folate metabolism gene 5,10-methylenetetrahydrofolate reductase (MTHFR) is associated with ADHD in myelomeningocele patients
Abstract
The objective of this study was to examine the relation between the 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene and behaviors related to attention- deficit/hyperactivity disorder (ADHD) in individuals with myelomeningocele. The rationale for the study was twofold: folate metabolizing genes, (e.g. MTHFR), are important not only in the etiology of neural tube defects but are also critical to cognitive function; and individuals with myelomeningocele have an elevated incidence of ADHD. Here, we tested 478 individuals with myelomeningocele for attention-deficit hyperactivity disorder behavior using the Swanson Nolan Achenbach Pelham-IV ADHD rating scale. Myelomeningocele participants in this group for whom DNAs were available were genotyped for seven single nucleotide polymorphisms (SNPs) in the MTHFR gene. The SNPs were evaluated for an association with manifestation of the ADHD phenotype in children with myelomeningocele. The data show that 28.7% of myelomeningocele participants exhibit rating scale elevations consistent with ADHD; of these 70.1% had scores consistent with the predominantly inattentive subtype. In addition, we also show a positive association between the SNP rs4846049 in the 3'-untranslated region of the MTHFR gene and the attention-deficit hyperactivity disorder phenotype in myelomeningocele participants. These results lend further support to the finding that behavior related to ADHD is more prevalent in patients with myelomeningocele than in the general population. These data also indicate the potential importance of the MTHFR gene in the etiology of the ADHD phenotype.
Conflict of interest statement
Figures


References
-
- Chen B, Carmichael S, Selvin S, Abrams B, Shaw G (2008) NTD prevalences in central California before and after folic acid fortification. Birth Defects Res A: Clin Mol Terat 82(8): 547–552. - PubMed
-
- Canfield M, Marengo L, Ramadhani T, Suarez L, Brender J, et al. (2009) The prevalence and predictors of anencephaly and spina bifida in Texas. Paediatr Perinat Epidem 23(1): 41–50. - PubMed
-
- Parker S, Mai C, Canfield M, Rickard R, Wang Y, et al. (2010) Updated national birth prevalence estimates for selected birth defects in the United States, 2004–2006. Birth Defects Res A: Clin Mol Teratol 88(12): 1008–1016. - PubMed
-
- Agiopian A, Canfield M, Olney R, Lupo P, Ramadhani T, et al. (2011) Spina bifida subtypes and sub-phenotypes by maternal race/ethnicity in the National Birth Defects Prevention Study. Am J Med Genet Part A. 9999: 1–7. - PubMed
-
- NINDS NIH (2007) “Spina bifida fact sheet.” Retrieved November 29, 2011, from http://www.ninds.nih.gov/disorders/spina_bifida/detail_spina_bifida.htm.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical